En iyi Pharma Manufacturing podcastleri (2024)

1
Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly] 4:26

6d ago4:26

4:26

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Novartis wins rare cancer pediatric indication for Lutathera The bad — BMS unveils cost-saving initiative, layoffs The ugly — McKinsey under fire for alleged role in opioid crisis…

1
Delivering Exceptional Clinical Trial Experiences for Patients 39:00

4d ago39:00

39:00

For more information, visit DPHARMconference.com.Pharma Talk Radio tarafından oluşturuldu

1
Optimizing the Integration of Mobile and Patient-Facing Tech in Clinical Trials 37:00

4d ago37:00

37:00

For more information, visit patientsaspartners.org.Pharma Talk Radio tarafından oluşturuldu

1
Psychedelic-Based Therapeutics for Generalized Anxiety Disorder (GAD) – Interview with Robert Barrow, CEO, MindMed 26:04

5d ago26:04

26:04

In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways…

1
ctDNA Potential for Prognostic Stratification, Tumor Insights & Drug Development 42:00

5d ago42:00

42:00

For more information, visit IO360summit.com.Pharma Talk Radio tarafından oluşturuldu

1
Developing Conditionally Active Antibodies: Interview with John K. Celebi, President & CEO, Sensei Bio. 28:16

12d ago28:16

28:16

In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Bio, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Sensei Biotherapeutics specializes in creating conditionally active antibodies. These are engineered to operat…

1
What to Expect at the 2024 Patients as Partners EU Conference 7:00

12d ago7:00

7:00

Valerie Bowling, Executive Director of the Conference Forum, discusses what attendees can expect at the 8th annual Patients as Partners EU conference, including keynotes, key topics, and the wide breadth of pharma companies present. For more information about the upcoming event, full agenda and speakers, visit https://patientsaspartnerseu.com/…

1
GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly] 4:10

13d ago4:10

4:10

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — GSK antibiotic hits phase 3 goals in gonorrhea The bad — Genentech ends $3B Adaptimmune T-cell collab The ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination…

1
BMS schizophrenia drug shines, Novartis axes jobs, Lilly compounding suit dismissed [The good, the bad, the ugly] 5:01

13d ago5:01

5:01

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — BMS schizophrenia drug shines in phase 3 trial The bad — Novartis to axe 680 jobs The ugly — Lilly compounding suit dismissedPharma Manufacturing tarafından oluşturuldu

1
Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya Therapeutics 34:02

19d ago34:02

34:02

In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021. Dr. Berman has over 18 years of entrepreneurial and industry experie…

1
2024 election's impact on manufacturing 32:57

23d ago32:57

32:57

Politics, whether we like them or not, weigh heavy on manufacturing’s future. In case you haven’t heard, it is an election year! Which means, global trade, regulations, immigration, national security and taxation will all be part of the national discourse, and all of those topics touch on manufacturing in one way or another. During this podcast, we…

1
Taking Lessons from Manufacturing Immunotherapies to Accelerate Development 44:00

24d ago44:00

44:00

For more information, visit IO360summit.com.Pharma Talk Radio tarafından oluşturuldu

1
Improving Cancer Screening Among Métis Communities: Interview with Margaret Froh, President, Métis Nation of Ontario 32:08

26d ago32:08

32:08

In this episode, Ayesha spoke with Margaret Froh, President of the Métis Nation of Ontario (MNO). Margaret is also a lawyer by training. The Métis are a distinct Indigenous people recognized in s.35 of Canada’s Constitution. Métis communities have their own shared customs, traditions and collective identities that are rooted in kinship, their speci…

1
Basilea grabs FDA nod, Verve halts gene editing trial, Amylyx pulls ALS drug [The good, the bad, the ugly] 3:47

27d ago3:47

3:47

Editor's Review: Week of April 1 Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Basilea Pharmaceutica receives FDA approval for its IV antibiotic The bad — Verve Therapeutics halts gene editing trial, again The ugly — Amylyx removes ALS treatment…

1
Enhancing Solubility with Novel Excipient Technologies 31:00

28d ago31:00

31:00

As new drugs in development have poorer solubility and bioavailability, there is a need for novel solubility enhancing polymers to improve drug loading and improve patient adherence. In this podcast, Nick DiFranco explains some of the shortcomings of traditional solubility enhancers as well as key considerations for novel technologies. Nick also pr…

1
Quick Hits: A Ground-Breaking Transaction 11:54

1M ago11:54

11:54

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Director Andy Labovitz about General Catalyst’s proposed acquisition of Summa Health – and whether that transaction represents the future for more health systems around the country. Cain Brothers is a division of KeyBanc Capital Markets.Cain Brothers, a division of KeyBanc Capital Markets tarafından oluşturuldu

1
Cell Therapies for Chronic Kidney Disease: Featuring Bruce Culleton, CEO, ProKidney 25:41

1M ago25:41

25:41

This episode features an interview with Bruce Culleton, MD, CEO, ProKidney, a late clinical-stage biotech company focused on the development of a pioneering cell therapy candidate that aims to transform the treatment landscape for chronic kidney disease. Prior to joining ProKidney in 2023, Dr. Culleton served as Vice President and General Manager a…

1
Measuring the Value of DCTs and Hybrid Models 32:00

1M ago32:00

32:00

For more information, visit DPHARMconference.com.Pharma Talk Radio tarafından oluşturuldu

1
[The good, the bad, the ugly] Editor's Review week of March 25 3:45

1M ago3:45

3:45

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Akebia Therapeutics' Vafseo anemia drug The bad — Bristol Myers Squibb's Crohn's disease drug disappoints The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment…

1
Navigating and Adopting Innovation in a Post- Pandemic World 26:00

1M ago26:00

26:00

For more information, visit DPHARMconference.com.Pharma Talk Radio tarafından oluşturuldu

1
Tackling Diabetic Kidney Disease: Featuring Robert Perkins, VP, US Medical Affairs (Renal), Bayer 18:06

1M ago18:06

18:06

In marking National Kidney Month, this episode features an interview with Robert Perkins, MD, Vice President, US Medical Affairs (Renal) at Bayer who spoke about kidney health and diabetes-inflicted chronic kidney disease. National Kidney Month is observed every March in the US to raise awareness about kidney health and promote preventive action. I…

1
[The good, the bad, the ugly] Editor's Review week of March 18 5:31

1M ago5:31

5:31

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Orchard gene therapy wins first FDA nod for rare pediatric disease The bad — Abiomed recalls heart pump instructions due to perforation risks The ugly — J&J files lawsuit against a former employee fo…

1
People in Life Sciences Series: Day-in-the-Life of a Pharmacovigilance Professional – Interview with Ashish Jain, Senior Director of Clinical Safety and PV, Curis 34:04

2M ago34:04

34:04

In this featured episode of Xtalks People in Life Sciences, Ayesha spoke with Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance (PV) at Curis, a pioneering biotech company specializing in cutting-edge cancer therapies. Jain shared his journey into clinical safety and PV, highlighting key milestones along the way. Delving into hi…

1
Quick Hits: The Case for Additional Partnership Between Skilled Nursing and Acute Care Providers 10:16

2M ago10:16

10:16

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Director Dom Porretta about the intense pressure on skilled nursing facilities and health systems and the need for fresh thinking on joint ventures that reduce discharge bottlenecks and improve day-to-day operations and overall care quality. Cain Brothers is a division of KeyBanc Capital …

1
[The good, the bad, the ugly] Editor's Review week of March 11 3:54

2M ago3:54

3:54

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Madrigal wins first FDA nod for NASH The bad — Acadia abandons plans to expand pimavanserin indications The ugly — BIO backs BIOSECURE Act, boots WuXi…

1
Turning a Search for Lung Cancer Biomarkers into a Patient Empowerment Community 21:00

2M ago21:00

21:00

Summary: In this podcast, Terri Conneran tells the story of how her cancer diagnosis and a search for relevant biomarkers turned into KRAS Kickers, a cancer research advocate community. For more information on PharmaTalk Radio podcasts, visit theconferenceforum.org.Pharma Talk Radio tarafından oluşturuldu

1
Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council 19:24

2M ago19:24

19:24

In this episode, Ayesha spoke with Jordyn Playne, President of the Métis Nation of Ontario Youth Council, a group of youth representatives from across Ontario who advocate on behalf of the concerns and interests of Métis youth at the provincial level. Jordyn is also a Clinical Consultant and Trainer at Waypoint Centre for Mental Health Care, as wel…

1
Engaging All Stakeholders for Clinical Trial Patient Engagement and Value 54:00

2M ago54:00

54:00

For more information, visit theconferenceforum.org.Pharma Talk Radio tarafından oluşturuldu

1
[The good, the bad, the ugly] Editor's Review week of March 4 4:16

2M ago4:16

4:16

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Boehringer Ingelheim to cap out-of-pocket inhaler prices The bad — Amylyx ALS drug falls short in phase 3 trial The ugly — FDA delays Eli Lilly Alzheimer's drug decision with last-minute AdComm…

1
Quick Hits: New Initiatives from CMS to Improve Access to Behavioral Health Services  7:32

2M ago7:32

7:32

In this Quick Hits House Calls, Dave talks to Cain Brothers’ Managing Director Erika Haanpaa about exciting new developments in access to behavioral health care. Cain Brothers is a division of KeyBanc Capital Markets.Cain Brothers, a division of KeyBanc Capital Markets tarafından oluşturuldu

1
Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments 23:37

2M ago23:37

23:37

In this episode, Ayesha spoke with H. B. Pierre Simon Jr., MBA, Vice President, Global Head of Marketing, Sight Sciences, about the evolving field of eye care. Sight Sciences is focused on developing and commercializing innovative solutions for eye diseases like glaucoma and dry eye disease to transform care and improve patients’ lives. Among some …

1
[The good, the bad, the ugly] Editor's Review week of February 29 3:07

2M ago3:07

3:07

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Iovance has launches Amtagvi The bad — FDA rejected Theratechnologies HIV instramuscular injection The ugly — BioMarin receives a subpoena from the DOJ…

1
EPISODE 10: Drug Bioavailability Enhancement 30:45

2M ago30:45

30:45

Simulating the Journey of Oral Medications: A Leap Towards Personalized Medicine In this episode, we are joined by Deanna Mudie, a senior principal engineer at Lonza, and John DiBella, president of PBPK & Cheminformatics at Simulations Plus, to discuss new techniques in enhancing the bioavailability of drugs. When you swallow a pill, have you ever …

1
[The good, the bad, the ugly] Editor's Review week of February 23 3:55

2M ago3:55

3:55

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Amtagvi approval The bad — Rapt clinical hold The ugly — Novavax and Gavi settlementPharma Manufacturing tarafından oluşturuldu

1
Rare Disease Day 2024: Highlighting Patient Stories and Advancements in Rare Disease Research 33:38

2M ago33:38

33:38

In this episode, Ayesha talked about Rare Disease Day 2024, a global movement held on the last day of February each year that focuses on raising awareness about rare diseases including their impact on patients’ lives. This year, Rare Disease Day falls on February 29, the rarest day in a leap year, making it even more special. Ayesha spoke about how…

1
Raising a modern CDMO 8:52

2M ago8:52

8:52

Across the board, the pharma industry is facing sky-high pressures to bring drugs to market quickly, safely and affordably. Facing this daunting landscape, pharma companies are enlisting the help of focused contract manufacturers to shape their therapies from the ground up. CDMOs, who so often go unnamed and unsung, have now become integral to forg…

1
Optimizing Medicine Development for Real-World Efficacy in Patients 25:00

2M ago25:00

25:00

About the episode: It's estimated that only 20% of health outcomes are due to clinical care, with the remaining 80% as a result of social determinants of health. Medicine development leaders must understand the broader context of patient lives in order to create therapies with real-world efficacy. In this podcast, Noël Theodosiou tells us how she's…

1
Biologics Development in Immunology and Inflammation — Featuring Amir Reichman, CEO of Scinai Immunotherapeutics 25:16

2M ago25:16

25:16

This episode features an interview with Amir Reichman, CEO of Scinai Immunotherapeutics, a biopharma company focused on developing, manufacturing and commercializing cutting-edge biological treatments within the inflammation and immunology (I&I) sector, with a primary focus on addressing autoimmune and infectious diseases. Scinai Immunotherapeutics…

1
Novel Approaches in Cancer Immunotherapy — Featuring OncoC4 founder, CEO and CSO Dr. Yang Liu and CFO Abid Ansari 24:42

3M ago24:42

24:42

This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, chief financial officer at OncoC4, a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. This includes first-in-class immunotherapy products such as novel antibodies and CAR T-cell…

1
New Targeted Treatments for Breast Cancer — Conversation with Dr. Carlos Doti, VP, US Medical Affairs Oncology, AstraZeneca 22:29

3M ago22:29

22:29

This episode features an interview with Carlos Doti, MD, Vice President, US Medical Affairs Oncology, AstraZeneca, about new breast cancer treatments. Dr. Doti is a hematologist by training and is passionate about developing treatments that have a real impact for people living with cancer across every aspect of their disease. Dr. Doti has worked in…

1
Exploring the Endocannabinoid System for Drug Development, Featuring Punit Dhillon, Chairman & CEO of Skye Bioscience 24:32

3M ago24:32

24:32

This episode features an interview with Punit Dhillon, Chairman & CEO of Skye Bioscience, a pharmaceutical company developing proprietary molecules to treat diseases involving inflammatory, fibrotic and metabolic conditions. Skye Bioscience is at the forefront of exploring the endocannabinoid system for drug development. Punit brings two decades of…

1
How CMOs can Support the Overarching Process of a Fundraising 27:00

3M ago27:00

27:00

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.Pharma Talk Radio tarafından oluşturuldu

1
Prioritizing Development Programs that Align with Fundraising Catalysts 31:00

3M ago31:00

31:00

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.Pharma Talk Radio tarafından oluşturuldu

1
Developing Internal and External Communication Strategies 32:00

3M ago32:00

32:00

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.Pharma Talk Radio tarafından oluşturuldu

1
Interacting with Different Types of Investors as a CMO 41:00

3M ago41:00

41:00

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.Pharma Talk Radio tarafından oluşturuldu

1
What CMOs Need to Know About Medical Affairs 31:00

3M ago31:00

31:00

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.Pharma Talk Radio tarafından oluşturuldu

1
Life Science Trends for 2024 43:03

3M ago43:03

43:03

In this episode, Ayesha talked about some of the trends in the life sciences to watch out for in 2024. From the increasing integration of artificial intelligence (AI) and machine learning (ML) tools in drug development to medically accurate health wearables, hear about the trends and innovations that will be shaping the life sciences this year. Aye…

1
Revolutionizing Orthopedic Joint Replacement — Interview with Ben Sexson, Co-Founder, CEO, Monogram Orthopedics 37:18

4M ago37:18

37:18

This episode features an interview with Ben Sexson, CFA, Co-Founder, CEO, Monogram Orthopedics at Monogram Orthopedics, a company dedicated to revolutionizing orthopedic joint replacement through surgical robotics. Monogram is focused on developing patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-…

1
Cognitive and Neuropsychiatric Disorders Drug Development, Featuring Dr. Adam Kaplin, Cofounder, President, CSO, MIRA Pharmaceuticals 56:50

4M ago56:50

56:50

This episode features an interview with Adam Kaplin, MD, PhD, Cofounder, President and Chief Scientific Officer at MIRA Pharmaceuticals, a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analogs for the treatment of anxiety and cognitive decline typically associated wi…

1
EPISODE 9: Capsules for Targeted Therapy Delivery 26:24

4M ago26:24

26:24

Capsules for Targeted Therapy: A Game-Changer in Modern Medicine In this episode we are joined by Vincent Jannin, Lonza's R&D Director, to explore Enprotect, the Award-Nominated Capsule Technology. Imagine starting your day with a simple capsule that goes beyond simply dissolving in your stomach to reach the place in your body where it is needed mo…

Dinlemeye Değer Podcast'ler

Pharma Manufacturing Podcastleri

Dinlemeye Değer Podcast'ler

Hızlı referans rehberi